Background: {#s1}
===========

Incorporation of prior pathway data into microarray analysis has become a popular research area in bioinformatics due to the advantages in providing the further biological interpretation compared to the single gene microarray analysis. These advantages have triggered various experiments and approaches in order to identify informative genes and pathways that contribute to certain cellular processes. Two most common approaches to identify the informative genes and pathways are enrichment analysis (EA) and machine learning (ML) approaches \[[@R01]\]. In EA approaches, genes are viewed as functional pathways where the pathways with large number of differentially expressed genes between two conditions are considered as significant \[[@R01]\]. While in ML approaches, the genes in the pathways are discriminated between two or more phenotypes of interests and the pathway with genes that improves the prediction of the phenotype considered as significant pathways.

However, there are some challenges in pathway analysis, such as, some pathways may be included with uninformative genes or perhaps informative genes were excluded \[[@R01]\]. Another concern is that usually pathway data are curated from the biological context free; it can be that only several genes take part in certain cellular process when it goes to the phenotype specific analysis (e.g. lung cancer research). In order to deal with the challenges in the quality of pathway data, several researchers in EA approaches attempt to refining the pathway data to specific conditions by removing the unaltered genes in the pathways, and including the additional information of the functional interpretation of the pathways or gene groups \[[@R01]\]. In ML approaches, several researchers have included the gene selection methods in order to select the informative genes within pathways before the pathway evaluation process \[[@R02], [@R03]\]. This is because, gene selection methods provide several advantages such as: (1) improves the classification accuracy, (2) removes uninformative genes, and (3) reduces computational time \[[@R13]\].

Misman *et al*. \[[@R04]\] had proposed the gSVM-SCAD in order to identify the significant genes and pathways, simultaneously dealing with the challenges in pathway data quality. gSVMSCAD is a hybrid method of support vector machines (SVM) and smoothly clipped absolute deviation (SCAD) with groupspecific tuning parameters that select the informative genes within pathways before the pathway evaluation process. gSVMSCAD had shown its superior performance in identifying significant genes and pathways compared to the hybrid of SVM and L1 penalty function (L1 SVM), and almost with all other 5 classifiers without gene selection methods \[[@R04]\]. However, in this work, we detected that gSVM-SCAD had some limitations.

A SCAD performance relies on the tuning parameter. If the tuning parameter is too small, it can bring little sparsity and over fit to the classifier model. While if it is too large, it can make very sparse to the classifier model but produced poor discriminating power \[[@R05], [@R06]\]. Therefore, it is important to choose an appropriate tuning parameter selector method for the gSVMSCAD, since the SCAD plays an important role in determining the true classification model for the SVM. The generalized cross validation (GCV) proposed by Fan and Li. \[[@R05]\] is widely used in the past literatures as a tuning parameter selector method for SVM-SCAD. Unfortunately, GCV had some limitations where it poorly performs when dealing with the low number of variables (genes) and large sample sizes \[[@R06]\]. This is due to the reason that usually some pathways contained not more than 100 genes and even some pathways contained less than 10 genes. We believed that this scenario can lead to the poor performance of SCAD in selecting the informative genes and simultaneously identifying significant genes. In order to surmount the limitation of the gSVM-SCAD, we propose the Btype generalized approximate cross validation (BGACV) as a new tuning parameter selector method for gSVM-SCAD. Our proposed method is denoted as gSVM-SCADBGACV.

Methodology: {#s2}
============

Experimental Data: {#s2a}
------------------

There are two types of data used: gene expression and pathway data. For gene expression data, the canine and lung cancer datasets were used to evaluate the performance of the gSVMSCADBGACV (the information of the datasets is shown in [Table 1](#SD1){ref-type="supplementary-material"}, see supplementary material). For the pathway data, there are total of 441 pathways with 129 taken from KEGG database while other 312 pathways curated from BioCarta database. Both gene expression and pathway data can be downloaded at <http://bioinformatics.med.yale.edu/pathwayanalysis/datasets.htm>. For the simulated data, total 1060 simulated genes are generated, where 848 genes are informative while other 212 genes are uninformative. The sample size for this experiment has been setup as 80. All 1060 genes are distributed into the Gi groups of genes where i = 1,...,15 and each group have a different size of genes. For the distribution of genes, each Gi contains i × 10 of genes. Moreover, 80% of genes in each group are informative. This creates 15 groups of genes with sizes varying from 10 to 150. The simulation data were created using the sim.data function in R package penalized SVM \[[@R14]\].

gSVM-SCAD with BGACV Tuning Parameter Method (The Proposed Method): {#s2b}
-------------------------------------------------------------------

Our proposed method (gSVM-SCADBGACV) consists of three steps as shown in [Figure 1](#F1){ref-type="fig"}. Step 1: group genes based on the pathway information provided by the pathway data. Step 2 is the most important step where the genes within pathways are evaluated using the SVM-SCAD, the uninformative genes are discarded from their pathway. In step 2.1, the proposed BGACV is used in order to select an appropriate tuning parameter for SVM-SCAD. In step 3, the classification error from the selected genes for each pathway is calculated. Step 1 and 3 is similar to the gSVM-SCAD but in step 2.1, there are some changes where BGACV is used instead of GACV.

BGACV is a modified version of GACV where "B" stands for Bayesian information criterion (BIC) model selector proposed by Schwarz \[[@R09]\]. Researchers believe that solution provided by BGACV is sparse and analogous to BIC \[[@R06]\]. The first BIC type of GCV for SCAD had been proposed by Wang *et al*. \[[@R10]\] and improved by Wang *et al*. \[[@R11]\] to be more robust when dealing with the diverging number of parameters. Despite showing good results when dealing with the diverging number of parameters, Wang *et al*. \[[@R11]\] admitted that their method still showed some limitation when dealing with the data with high number of samples and low number of variables. Therefore, we used the GACV formula \[[@R12]\] and transformed the GACV formula into BGACV. The GACV proved it robustness when dealing with data with high number of samples and low number of variables \[[@R12]\]. The formula of GACV is given in [supplementary material](#SD1){ref-type="supplementary-material"}.

Discussion: {#s3}
===========

Simulation Study: {#s3a}
-----------------

The purpose of this experiment is to evaluate the performance of both GACV and BGACV and providing the appropriate for gSVM-SCAD in a situation where the sizes of pathways are small and medium. Both gSVM-SCADBGACV and gSVMSCAD were run for 10 times for each group of genes and the averages of the classification error are recorded. The results are presented in [Figure 2](#F2){ref-type="fig"}.

From the [Figure 2](#F2){ref-type="fig"}, it is shown that BGACV obtained less classification error compared to GACV in group of genes sizes 10, 20, and 60 with 0.02, 0.06, and 0.06 less, respectively. All these groups of genes contained a size of genes smaller than the sample size (sample size = 80). While for the groups of genes that contained the size of genes with equal and bigger than sample size, there are no different results between both BGACV and GACV methods. From the results above, it is shown that BGACV can deal with the small group of genes compared to GACV by producing less misclassification error. While for groups of genes that contained larger size of genes than the sample size, both BGACV and GACV methods have the same performance. Our analysis shows that BGACV are more robust and consistent in providing the near optimal for SCAD when dealing with the diverging numbers of parameters, especially when the number of genes are smaller than the number of samples.

Performance Evaluation: {#s3b}
-----------------------

A gSVM-SCADBGACV is also used on the lung cancer and canine datasets to evaluate the performance of the proposed method. From this experiment, results from the 10-fold cross validation (10-fold CV) were recorded and compared with other 5 supervised machine learning methods. The 5 supervised machine learning methods are PathwayRF \[[@R15]\], neural networks, k-nearset neighbour with 1 neighbour (KNN1) and 3 neighbours (KKN3), and linear discriminant analysis (LDA). The results of the gSVM-SCADBGACV performance against other machine learning methods are shown in [Table 2](#SD1){ref-type="supplementary-material"} (see supplementary material).

For the canine dataset in [Table 2](#SD1){ref-type="supplementary-material"} (see supplementary material), it is interesting to note that gSVM-SCADBGACV outperforms gSVM-SCAD and the other machine learning methods with 85.95% accuracy. The gSVM-SCADBGACV achieved 4.87% higher than gSVM-SCAD, 3.62% higher than neural networks, slightly 0.04% higher than PathwayRF, and 4.96% higher than KNN1 and KNN3 respectively, and 9.34% higher than LDA. For the lung cancer dataset, gSVM-SCADBGACV also showed a significant improvement with 76.55% accuracy and 2.78% higher than gSVM-SCAD. While with other methods, gSVMSCADBGACV obtained 4.55% higher than PathwayRF, 6.16% higher than neural networks, 14.82% higher than KNN1, 11.75% higher than KNN3, 13.31% higher than LDA, 21.41% higher than L1 SVM, 23.05% higher than SVM-SCAD.

From these results, it is proved that BGACV plays an important role in increasing the performance of SCAD in gSVM-SCAD. For the canine dataset, gSVM-SCAD showed quite poor performance, ranked third behind neural networks and PathwayRF. However, when BGACV is applied to the gSVMSCAD, it showed a significant improvement even it obtained slightly higher than PathwayRF result. This is because, BGACV is consistently identified nearly optimal for SCAD and simultaneously provides nearly unbiased coefficient estimation when dealing with large coefficients. The results from the gSVM-SCADBGACV show significant achievement, since the pathway analysis usually dealing with the lower size of genes and larger size of samples.

Conclusion: {#s4}
===========

In this work, the proposed gSVM-CADBGACV is shown to outperform the gSVM-SCAD and other supervised machine learning methods. It is also shown that, a tuning parameter selector method plays an important role in gSVM-SCAD in dealing with the small genes size and large sample size that usually happened in pathway-based microarray analysis. The gSVM-SCADBGACV consistently showed better performance from the simulation study, the 10-fold CV accuracy, and in biological validation compared to gSVM-SCAD (see [supplementary material](#SD1){ref-type="supplementary-material"} for biological validation results). We have only focused on static gene expression data; however, our approach can be implemented with modification to time-course or survival gene expression data.
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